Yu-Hui Liu

TL;DR: The association between infectious burden (IB) and Alzheimer's disease (AD) was examined and the overall burden of prior infections contributes to cardiovascular diseases and stroke.

TL;DR: This study is the first to reveal that blood-derived Aβ can enter the brain, form the Aβ-related pathologies and induce functional deficits of neurons and provides evidence that supports the development of therapies for AD by targeting Aβ metabolism in both the brain and the periphery.

TL;DR: Restoration of the BDNF level attenuated behavioral deficits, prevented neuron loss, alleviated synaptic degeneration and reduced neuronal abnormality, but did not affect tau hyperphosphorylation level in the brains of P301L mice, suggesting that the gene delivery of BDNF is a promising treatment for tau-related neurodegeneration for AD and other neuro degenerative disorders with tauopathy.

TL;DR: Edaravone, a free radical scavenger that is marketed for acute ischemic stroke, has a potent capacity of inhibiting Aβ aggregation and attenuating Aβ-induced oxidation in vitro and holds a promise as a therapeutic agent for AD by targeting multiple key pathways of the disease pathogenesis.

TL;DR: The role of infection in the etiology of PD is supported as a composite serologic measure of exposure to common infectious pathogens as well as bacterial burden, viral burden and viral burden were independently associated with PD.